US Food and Drug Administration (FDA) has said Ranbaxy is not taking adequate corrective measures to meet regulatory requirements even after receiving warning letters from it.
“It is apparent that Ranbaxy’s attempts to make global corrections after past regulatory actions by the FDA have been inadequate,” FDA said in a warning letter posted on its website and issued by it on December 21, 2009, to the US-based subsidiary Ohm Laboratories for violating norms of current good manufacturing practice.